Drug Shortage Oversight Remains Key GAO Concern As FDA Is Again Deemed “High-Risk”
This article was originally published in The Pink Sheet Daily
Executive Summary
Report again calls for improvement in oversight of medical device recalls by FDA, as well as for increased inspections of foreign establishments that make medical products for the U.S. market.
You may also be interested in...
GAO Calls For Reforms In FDA Oversight Of Device Recalls
The Government Accountability Office is urging FDA to clarify and strengthen its oversight of medical device recalls.
FDA Oversight Of Medical Products Remains A "High-Risk" Concern For GAO
Resource management and strategic planning, mounting challenges associated with globalization, oversight of post-market product safety, and the agency's efforts to address devices that are class III but continue to reach the market through the 510(k) pathway top GAO's list.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.